⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FATE News
Fate Therapeutics, Inc.
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
globenewswire.com
FATE
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
FATE
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
globenewswire.com
FATE
The $13 Million Company Teaching the Immune System to Hunt Cancer
prnewswire.com
NKTX
GTBP
IBRX
FATE
ARTV
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
globenewswire.com
FATE
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
prnewswire.com
LCTX
FATE
GERN
BIOA
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
prnewswire.com
NKTX
GTBP
IBRX
FATE
INMB
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
prnewswire.com
GTBP
ARTV
FATE
IBRX
CHRS
Form 8-K
sec.gov
FATE
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
globenewswire.com
FATE